CA2651654A1 - Substituted azaspiro derivatives - Google Patents

Substituted azaspiro derivatives Download PDF

Info

Publication number
CA2651654A1
CA2651654A1 CA002651654A CA2651654A CA2651654A1 CA 2651654 A1 CA2651654 A1 CA 2651654A1 CA 002651654 A CA002651654 A CA 002651654A CA 2651654 A CA2651654 A CA 2651654A CA 2651654 A1 CA2651654 A1 CA 2651654A1
Authority
CA
Canada
Prior art keywords
cyclobutyl
diazaspiro
undecane
undec
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002651654A
Other languages
English (en)
French (fr)
Inventor
Yuelian Xu
Timothy M. Caldwell
Linghong Xie
Bertrand L. Chenard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2651654A1 publication Critical patent/CA2651654A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002651654A 2006-05-08 2007-05-08 Substituted azaspiro derivatives Abandoned CA2651654A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74668006P 2006-05-08 2006-05-08
US60/746,680 2006-05-08
US11/745,448 US20080247964A1 (en) 2006-05-08 2007-05-07 Substituted azaspiro derivatives
US11/745,448 2007-05-07
PCT/US2007/011135 WO2007133561A2 (en) 2006-05-08 2007-05-08 Substituted azaspiro derivatives

Publications (1)

Publication Number Publication Date
CA2651654A1 true CA2651654A1 (en) 2007-11-22

Family

ID=38694439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002651654A Abandoned CA2651654A1 (en) 2006-05-08 2007-05-08 Substituted azaspiro derivatives

Country Status (8)

Country Link
US (1) US20080247964A1 (https=)
EP (1) EP2021004A4 (https=)
JP (1) JP2009536651A (https=)
KR (1) KR20090015956A (https=)
AU (1) AU2007249925A1 (https=)
CA (1) CA2651654A1 (https=)
IL (1) IL195132A0 (https=)
WO (1) WO2007133561A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239170B (zh) * 2008-12-05 2014-08-20 赛诺菲 取代的四氢吡喃螺吡咯烷酮和哌啶酮及其制备和治疗用途

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
TW201206898A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
EP2569297A1 (en) 2010-05-11 2013-03-20 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
TW201206889A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
WO2011143162A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
AR083718A1 (es) 2010-05-11 2013-03-20 Sanofi Aventis Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換n−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
WO2011143155A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JP6215315B2 (ja) * 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
US9096528B2 (en) 2012-07-04 2015-08-04 Agro-Kanesho Co., Ltd. 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient
US8729263B2 (en) * 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CN103288845B (zh) * 2013-05-24 2015-05-20 武汉工程大学 螺环化合物2,4,8,10-四羰基-3,9-二氧杂螺环[5,5]十一烷及其合成方法
EP4105208A1 (en) * 2013-07-31 2022-12-21 Novartis AG 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
HUE038764T2 (hu) * 2014-03-17 2018-11-28 Remynd Nv 2,7-Diazaspiro[3.5]nonán vegyületek
DK3212637T3 (da) 2014-10-31 2021-07-12 Indivior Uk Ltd Dopamin-d3-receptorantagonistforbindelser
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP3256126B1 (en) * 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EA201800367A1 (ru) * 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
WO2018068296A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
HRP20240935T1 (hr) 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
CN109485648A (zh) * 2018-12-17 2019-03-19 无锡合全药业有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-8-甲酸基酯的制备方法
JP7649257B2 (ja) 2019-05-13 2025-03-19 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物
CN117177744A (zh) 2021-01-29 2023-12-05 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
MX2023015436A (es) 2021-06-26 2024-02-21 Cedilla Therapeutics Inc Inhibidores de cdk2 y metodos de uso de los mismos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH375356A (de) * 1959-03-25 1964-02-29 Sandoz Ag Verfahren zur Herstellung von neuen substituierten Succinimiden
US3106552A (en) * 1960-07-19 1963-10-08 Geschickter Fund Med Res Nu-substituted azaspiranes and azaspirane-diones and processes for their preparation
US3282947A (en) * 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
EP0621267A1 (en) * 1993-04-07 1994-10-26 Shell Internationale Researchmaatschappij B.V. Spiropiperidine derivatives and their use as fungicides
US5451578A (en) * 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
GB2309167A (en) * 1997-05-10 1997-07-23 Anormed Inc The use of azaspiranes in the treatment of Alzheimer's disease
DE69900220T2 (de) * 1998-06-12 2002-05-08 F. Hoffmann-La Roche Ag, Basel Diaza-spiro[3,5]nonan-Derivate
WO2004005293A2 (en) * 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
CA2518357A1 (en) * 2003-03-10 2004-09-23 Callisto Pharmaceuticals, Inc. Method of treating cancer with azaspirane compositions
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
JPWO2005047286A1 (ja) * 2003-11-13 2007-05-31 小野薬品工業株式会社 スピロ複素環化合物
AU2005277410B2 (en) * 2004-08-20 2010-06-24 Targacept, Inc. The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
WO2006040329A1 (en) * 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
EP1917264B1 (en) * 2005-06-28 2010-11-17 NeuroSearch A/S Novel 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239170B (zh) * 2008-12-05 2014-08-20 赛诺菲 取代的四氢吡喃螺吡咯烷酮和哌啶酮及其制备和治疗用途

Also Published As

Publication number Publication date
US20080247964A1 (en) 2008-10-09
JP2009536651A (ja) 2009-10-15
IL195132A0 (en) 2009-09-22
AU2007249925A1 (en) 2007-11-22
KR20090015956A (ko) 2009-02-12
EP2021004A2 (en) 2009-02-11
WO2007133561A3 (en) 2008-10-02
WO2007133561A2 (en) 2007-11-22
EP2021004A4 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
CA2651654A1 (en) Substituted azaspiro derivatives
EP1998620B1 (en) Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
US20080051387A1 (en) Tetrahydropyrido[3,4-d]pyrimidines and related analogues
CA2690748A1 (en) Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
US7851474B2 (en) Dipiperazinyl ketones and related analogues
US8440694B2 (en) Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor
US20100317679A1 (en) Substituted aryl-fused spirocyclic amines
JP2023522951A (ja) ムスカリンアセチルコリン受容体m4のアンタゴニストとしての縮合置換ヒドロピロール
JP2023522959A (ja) ムスカリンアセチルコリン受容体m4のアンタゴニストとしての縮合置換ヒドロピロール
CN101466375A (zh) 取代氮杂螺环衍生物
WO2009100120A2 (en) Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
HK1143588B (en) Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130508